Issue 11/2012
Content (9 Articles)
Cost-Effectiveness Analysis of Therapies for Chronic Kidney Disease Patients on Dialysis
Daniel T. Grima, Lisa M. Bernard, Elizabeth S. Dunn, Philip A. McFarlane, David C. Mendelssohn
Omalizumab for the Treatment of Severe Persistent Allergic Asthma in Children Aged 6–11 Years
Jane Burch, Susan Griffin, Claire McKenna, Simon Walker, James Paton, Kath Wright, Nerys Woolacott
The Burden of Moderate to Severe Psoriasis
Giovanna Raho, Daniela Mihajlova Koleva, Livio Garattini, Luigi Naldi
Cost Effectiveness of Hepatitis C-Related Interventions Targeting Substance Users and Other High-Risk Groups
Ava John-Baptiste, Man Wah Yeung, Victoria Leung, Gabrielle van der Velde, Murray Krahn
Losing Sight of the Wood for the Trees
Paul Dolan, Henry Lee, Tessa Peasgood
A 3-Dimensional View of Access to Licensed and Subsidized Medicines under Single-Payer Systems in the US, the UK, Australia and New Zealand
Rajan Ragupathy, Katri Aaltonen, June Tordoff, Pauline Norris, David Reith
The Cost Effectiveness of Genetic Testing for CYP2C19 Variants to Guide Thienopyridine Treatment in Patients with Acute Coronary Syndromes
Laura Panattoni, Paul M. Brown, Braden Te Ao, Mark Webster, Patrick Gladding
The General Public’s Willingness to Pay for Tax Increases to Support Unrestricted Access to an Alzheimer’s Disease Medication
Mark Oremus, Jean-Eric Tarride, Parminder Raina, Lehana Thabane, Gary Foster, Charlie H. Goldsmith, Natasha Clayton
Erratum to Cost utility of tumour necrosis factor-α inhibitors for rheumatoid arthritis: an application of Bayesian methods for evidence synthesis in a Markov model
Nguyen C. M., Bounthavong M., Mendes M. A. S., Christopher M. L. D., Tran J. N., Kazerooni R., Morreale A. P.